See more : Maezawa Kyuso Industries Co.,Ltd. (6485.T) Income Statement Analysis – Financial Results
Complete financial analysis of OrbusNeich Medical Group Holdings Limited (6929.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OrbusNeich Medical Group Holdings Limited, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- China Gas Holdings Limited (0384.HK) Income Statement Analysis – Financial Results
- Dynagreen Environmental Protection Group Co., Ltd. (1330.HK) Income Statement Analysis – Financial Results
- Mintech (452200.KQ) Income Statement Analysis – Financial Results
- Lumosa Therapeutics Co., Ltd. (6535.TWO) Income Statement Analysis – Financial Results
- Camarico Investment Group Ltd. (CIG.CN) Income Statement Analysis – Financial Results
OrbusNeich Medical Group Holdings Limited (6929.HK)
About OrbusNeich Medical Group Holdings Limited
OrbusNeich Medical Group Holdings Limited, an investment holding company, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People's Republic of China, and the United States. The company offers semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, coronary stents for implantation, non-compliant balloons for post-dilatation, and specialty catheters. Its product portfolio covers various treatment processes in percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. The company was founded in 2001 and is headquartered in Shatin, Hong Kong. OrbusNeich Medical Group Holdings Limited is a subsidiary of Harmony Tree Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 153.87M | 136.82M | 116.46M | 88.47M | 96.34M |
| Cost of Revenue | 47.37M | 44.37M | 35.29M | 30.45M | 30.90M |
| Gross Profit | 106.50M | 92.46M | 81.17M | 58.02M | 65.45M |
| Gross Profit Ratio | 69.22% | 67.57% | 69.70% | 65.58% | 67.93% |
| Research & Development | 14.81M | 14.11M | 12.15M | 12.58M | 9.59M |
| General & Administrative | 18.91M | 22.57M | 19.96M | 14.30M | 15.41M |
| Selling & Marketing | 35.93M | 32.56M | 30.10M | 26.69M | 32.25M |
| SG&A | 54.84M | 55.13M | 50.06M | 40.99M | 49.48M |
| Other Expenses | -3.09M | 9.00K | -14.94M | -43.00K | 0.00 |
| Operating Expenses | 66.56M | 68.33M | 60.82M | 51.16M | 57.46M |
| Cost & Expenses | 113.93M | 112.69M | 96.11M | 81.61M | 88.36M |
| Interest Income | 10.67M | 2.39M | 12.00K | 12.00K | 480.00K |
| Interest Expense | 142.00K | 1.46M | 5.61M | 1.40M | 501.00K |
| Depreciation & Amortization | 4.21M | 3.88M | 4.02M | 4.09M | 2.39M |
| EBITDA | 53.97M | 27.14M | 8.31M | 12.75M | 10.04M |
| EBITDA Ratio | 35.07% | 21.37% | 7.15% | 13.43% | 10.42% |
| Operating Income | 39.94M | 21.07M | 19.44M | 8.69M | 7.65M |
| Operating Income Ratio | 25.96% | 15.40% | 16.69% | 9.83% | 7.94% |
| Total Other Income/Expenses | 9.69M | 719.00K | -20.76M | -1.44M | -482.00K |
| Income Before Tax | 49.63M | 21.79M | -1.32M | 7.26M | 7.51M |
| Income Before Tax Ratio | 32.25% | 15.93% | -1.13% | 8.20% | 7.79% |
| Income Tax Expense | 4.56M | 3.30M | 3.13M | 184.00K | 549.00K |
| Net Income | 45.07M | 18.49M | -4.44M | 7.07M | 6.96M |
| Net Income Ratio | 29.29% | 13.51% | -3.82% | 7.99% | 7.22% |
| EPS | 0.05 | 0.03 | -0.01 | 0.01 | 0.01 |
| EPS Diluted | 0.05 | 0.03 | -0.01 | 0.01 | 0.01 |
| Weighted Avg Shares Out | 833.16M | 724.09M | 576.92M | 576.94M | 579.83M |
| Weighted Avg Shares Out (Dil) | 832.96M | 776.39M | 576.90M | 576.90M | 576.90M |
Source: https://incomestatements.info
Category: Stock Reports